newsfilter
← Latest News
PR Newswire·

Kintara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

SAN DIEGO, Nov. 30, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,